Literature DB >> 7791386

Extrapulmonary lymphangioleiomyomatosis and lymphangiomatous cysts in tuberous sclerosis complex.

V E Torres1, J Björnsson, B F King, R Kumar, H Zincke, E S Edell, T O Wilson, R R Hattery, M R Gomez.   

Abstract

OBJECTIVE: To describe the clinical manifestations, imaging findings, and histologic features of extrapulmonary lymphangioleiomyomatosis (LAM) in the tuberous sclerosis complex (TSC).
DESIGN: We retrospectively reviewed institutional medical records since 1940 to identify patients with TSC and extrapulmonary LAM.
MATERIAL AND METHODS: Of 403 patients with TSC, 3 had pulmonary and extrapulmonary LAM and retroperitoneal lymphangiomatous cysts. The clinical, imaging, and histologic features of these three patients were summarized, including analysis of biopsy specimens by conventional histology, immunohistology, radiolabeled ligand-binding assays, and tissue culture.
RESULTS: The three young women had characteristic dermatologic findings of TSC and pulmonary LAM. Two patients were of normal intelligence, and one had a recent history of contraceptive use. All three patients had intra-abdominal lymphangiomatous cysts, uterine LAM, and renal angiomyolipomas. Renal and uterine biopsy specimens demonstrated positive immunostaining for melanoma-related antigens and expression of estrogen and progesterone receptors by ligand-binding assay and immunohistology. Cells cultured from LAM tissue of one of the patients exhibited a mitogenic response to estradiol.
CONCLUSION: Clinically significant extrapulmonary LAM is a rare manifestation of TSC and may occur in women with this disease who also have pulmonary LAM. The clinical features of these patients confirm the importance of sex steroids in the development of these lesions. Immunohistochemical findings suggest that LAM and angiomyolipomas have a neuroectodermal origin. The development of lymphangiomatous cysts in these patients is probably due to smooth muscle proliferation in lymph vessels, which can result in lymphatic obstruction.

Entities:  

Mesh:

Year:  1995        PMID: 7791386     DOI: 10.4065/70.7.641

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

Review 1.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

2.  CT and MR imaging findings of lymphangioleiomyomatosis involving the uterus and pelvic cavity.

Authors:  You Sung Kim; Sung Eun Rha; Jae Young Byun; Ahwon Lee; Jong Sup Park
Journal:  Korean J Radiol       Date:  2011-03-03       Impact factor: 3.500

3.  Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis.

Authors:  T A Smolarek; L L Wessner; F X McCormack; J C Mylet; A G Menon; E P Henske
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

Review 4.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

Review 5.  The pathogenesis and imaging of the tuberous sclerosis complex.

Authors:  Henry J Baskin
Journal:  Pediatr Radiol       Date:  2008-04-15

6.  Uterine PEComas: A Morphologic, Immunohistochemical, and Molecular Analysis of 32 Tumors.

Authors:  Jennifer A Bennett; Ana C Braga; Andre Pinto; Koen Van de Vijver; Kristine Cornejo; Anna Pesci; Lei Zhang; Vicente Morales-Oyarvide; Takako Kiyokawa; Gian Franco Zannoni; Joseph Carlson; Tomas Slavik; Carmen Tornos; Cristina R Antonescu; Esther Oliva
Journal:  Am J Surg Pathol       Date:  2018-10       Impact factor: 6.394

7.  Uterine PEComa: appraisal of a controversial and increasingly reported mesenchymal neoplasm.

Authors:  Oluwole Fadare
Journal:  Int Semin Surg Oncol       Date:  2008-03-06

Review 8.  High Mobility Group AT-Hook 2 (HMGA2) Oncogenicity in Mesenchymal and Epithelial Neoplasia.

Authors:  Uchenna Unachukwu; Kiran Chada; Jeanine D'Armiento
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.